Phase III data has shown that tucatinib in combination with trastuzumab and capecitabine improves progression-free and overall survival in HER2-positive breast cancer patients previously treated with trastuzumab, pertuzumab and trastuzumab emtansine [88]. This evidence concerns the gene ERBB2 and breast carcinoma.